Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
compounded under Section 503A for individual prescriptions Hepatic impairment data / no controlled pharmacokinetic studies in liver disease populations Copper clearance / 85-95% of circulating copper is bound to ceruloplasmin, which is synthesized exclusively in the liver [1] Wilson disease parallel / hepatic copper accumulation can reach 250+ mcg/g dry weight in impaired biliary excretion [2] Child-Pugh A / may proceed with standard dosing and baseline copper labs Child-Pugh B / dose reduction recommended with monthly copper monitoring Child-Pugh C / use generally not recommended due to impaired biliary copper excretion Standard compounded dose / 1-2 mg subcutaneously daily or 3 times weekly Key monitoring labs / serum copper, ceruloplasmin, 24-hour urine copper, liver function tests What Is GHK-Cu and How Does It Work
Chemotherapy Recovery Chemotherapy is effective at targeting cancer cells, but it can also affect healthy tissues, leading to fatigue, oxidative stress, weakened immunity, and organ toxicity
As demonstrated above, the activation of AMPK induces the inhibitory phosphorylation of ACC
this summary covers the well-studied copper tripeptide GHK-Cu (glycyl-L-histidyl-L-lysineCu)
A compound that lacks a 503A pathway cannot be legitimately compounded for patients in the United States
A Cautionary Account that GLP-1 Receptor Agonists May be Too Effective for Unmonitored Weight Loss
US$ 27.65
US$ 27.30
US$ 24.28
US$ 27.46
US$ 21.10
